NeoImmuneTech, Inc.
950220·KOSDAQ·9 grantsAmendments merged
- Shares granted, cumulative
- 6,948,560shares
- Next lockup release
- D-586
- 2028-03-27
Against the share price
At the 2026-08-18 close- Shares with a reason to exercise
- 1,000,000 shares
- 2.92% of shares outstanding
- Sellable right now
- None
- Above the strike price, but the lockup has not ended
- Unrealized paper gain (to the employees)
- ₩1.1B
Potential dilution
Shares by strike price
- ₩14,3502.2M shares
- ₩14,300508K shares
- ₩10,050339K shares
- ₩7,330508K shares
- ₩4,220315K shares
- ₩3,440714K shares
- ₩1,850353K shares
- ₩1,7601M shares
- ₩1,676Latest price
- ₩5701M shares
Below the line (strike < Latest price) sits above the strike price: 1M shares, 14% of the shares still inside their exercise window.
Options the share price has risen past gain a reason to be exercised and sold once the lockup ends. Filings do not show what has already been exercised or forfeited, so these figures are on a cumulative grants basis and the shares actually outstanding may be fewer.
Share price vs. strike price
A strike price is fixed on the grant date; only the share price moves. Where the price line crosses a dashed line is when that block of options first had a reason to be exercised.
- Strike ₩14,3502.2M shares
- Strike ₩5701M sharesabove
- Strike ₩1,7601M shares
- Strike ₩3,440714K shares
Recipients by role
- Registered director5 people11%
- Unregistered officer12 people20%
- Employee139 people69%
- Other · unknown1 person0%
Sorted from the relation text written in the filings (157 recipients). Officers of affiliates and subsidiaries are counted as unregistered officers.
Shares granted by year
Cumulative grants per recipient
13 named · 140 withheld| Recipient | Shares, cumulative | Average strike | Exercisable | Paper gain |
|---|---|---|---|---|
| 411,0758.1% | ₩13,017 | 411,075 | — | |
| 200,0003.9% | ₩1,760 | 200,000 | — | |
| 200,0003.9% | ₩570 | — | ₩221.2M | |
| 167,5003.3% | ₩4,220 | 167,500 | — | |
| 100,0002.0% | ₩1,850 | 100,000 | — | |
| 82,2151.6% | ₩13,061 | 82,215 | — | |
| 82,2151.6% | ₩13,017 | 82,215 | — | |
| 82,2151.6% | ₩13,017 | 82,215 | — | |
| 50,0001.0% | ₩7,330 | 50,000 | — | |
| 48,5751.0% | ₩3,440 | 48,575 | — |
Recipients granted less than 10 in 10,000 of total shares issued have their names withheld under the disclosure rules; they cannot be split apart, so they are grouped into one row. Rows that pack several people onto one line, such as “OOO and 6 others”, are grouped there too, with the headcount read from that text — the split between them is never disclosed, so “my share” can only be prefilled with the per-person average. Filings carry no employee number or year of birth, so people with the same name are added together as one. “Exercisable” counts shares whose lockup has already ended, and any paper gain accrues to the employees holding the options.
Grant history · lockup schedule
Exercisable shares over time
It rises on the day a lockup ends and falls on the day an exercise window closes. Options actually exercised are not subtracted, because only executives have to report them.
20261 grant · 1,000,000 sharesReleases 2028-03-27
- Granted2026-03-27
- Exercise starts2028-03-27
- Exercise ends2036-03-27
- Shares granted
- 1,000,000shares
- Strike price
- 570KRW
- Grant method
- New share issuance
- Approved by
- Shareholders' meeting
Above the strike price₩1,106 per share₩1.1BReport on grant of stock options
20241 grant · 1,000,000 shares
- Granted2024-03-29
- Exercise starts2026-03-29
- Exercise ends3034-03-29
- Shares granted
- 1,000,000shares
- Strike price
- 1,760KRW
- Grant method
- New share issuance
- Approved by
- Shareholders' meeting
Below the strike priceShare price below the strike — no reason to exerciseReport on grant of stock options
20232 grants · 1,066,930 shares
- Granted2023-09-27
- Exercise starts2025-09-27
- Exercise ends2033-09-27
- Shares granted
- 352,710shares
- Strike price
- 1,850KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exerciseReport on grant of stock options
- Granted2023-03-31
- Exercise starts2025-03-31
- Exercise ends2033-03-31
- Shares granted
- 714,220shares
- Strike price
- 3,440KRW
- Grant method
- New share issuance
- Approved by
- Shareholders' meeting
Below the strike priceShare price below the strike — no reason to exerciseReport on grant of stock options
20222 grants · 822,565 shares
- Granted2022-09-30
- Exercise starts2024-09-30
- Exercise ends2032-09-30
- Shares granted
- 314,565shares
- Strike price
- 4,220KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exerciseReport on grant of stock options
- Granted2022-03-31
- Exercise starts2024-03-31
- Exercise ends2032-03-31
- Shares granted
- 508,000shares
- Strike price
- 7,330KRW
- Grant method
- New share issuance
- Approved by
- Shareholders' meeting
Below the strike priceShare price below the strike — no reason to exerciseReport on grant of stock options
20213 grants · 3,059,065 shares
- Granted2021-09-28
- Exercise starts2023-09-28
- Exercise ends2031-09-28
- Shares granted
- 338,500shares
- Strike price
- 10,050KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exercise[Amended] Report on grant of stock options
- Granted2021-03-31
- Exercise starts2023-03-31
- Exercise ends2033-03-30
- Shares granted
- 507,500shares
- Strike price
- 14,300KRW
- Grant method
- New share issuance
- Approved by
- Shareholders' meeting
Below the strike priceShare price below the strike — no reason to exerciseReport on grant of stock options
- Granted2021-03-16
- Exercise starts2023-03-16
- Exercise ends2031-03-15
- Shares granted
- 2,213,065shares
- Strike price
- 14,350KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exercise[Amended] Report on grant of stock options
Every figure here is parsed mechanically from the original DART filing (document.xml). “Exercise starts (estimated)” means the filing did not state an exercise period, so the date is the grant date plus two years under Article 340-2(4) of the Korean Commercial Act and may differ from the actual terms. Always read the original filing before making any decision.